董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Katharyn Field | 女 | Independent Director | 42 | 未披露 | 未持股 | 2026-02-02 |
| Archelle Georgiou | -- | Independent Director | -- | 7.07万美元 | 0.0028 | 2026-02-02 |
| Mika Grasso | 男 | Independent Director | 28 | 未披露 | 未持股 | 2026-02-02 |
| Gregory D. Waller | 男 | Independent Director | 76 | 8.00万美元 | 0.0028 | 2026-02-02 |
| John L. Erb | 男 | Chairman of the Board,Chief Executive Officer and President | 77 | 37.52万美元 | 0.08 | 2026-02-02 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Neil P. Ayotte, Esq | -- | Senior Vice President, General Counsel, Secretary and Chief Compliance Officer | -- | 35.09万美元 | 0.0001 | 2026-02-02 |
| Carisa Schultz | 女 | Principal Financial Officer and Principal Accounting Officer | 48 | 未披露 | 未持股 | 2026-02-02 |
| John L. Erb | 男 | Chairman of the Board,Chief Executive Officer and President | 77 | 37.52万美元 | 0.08 | 2026-02-02 |
董事简历
中英对照 | 中文 | 英文- Katharyn Field
-
Katharyn Field自2025年6月起担任董事和执行官，并于2024年10月至2025年6月担任独立董事。在为公司服务期间，Field女士还在Virpax Pharmaceuticals Inc.担任独立董事和审计委员会成员，该公司是一家专业制药公司，专注于凭借其旗舰产品利用专有脂质体封装（纳斯达克：VRPX）开创先进的医疗保健解决方案，自2024年7月起，在iSpecimen Inc.担任独立董事和审计委员会成员，该公司提供技术，将需要人类生物流体、组织和活细胞进行研究的生命科学研究人员与全球医疗保健提供者组织（纳斯达克：ISPC）中可用的生物样本连接起来，自2024年9月起，自2022年7月起担任Halo Collective Inc.的首席执行官和董事会主席，该公司是一家在加拿大和美国从事大麻和大麻提取物的种植、制造、运输和分销的公司（OTC：HCANF），自2022年6月起担任Akanda Corporation的临时首席执行官和执行董事，Akanda Corporation是一家在全球范围内从事基于大麻的药用产品的种植、制造和分销的公司（纳斯达克：AKAN）。在加入公司之前，Field女士曾于2013年1月至2017年1月在美国园艺种植商Costa Farms担任董事，于2017年1月至2018年1月担任顾问，于2018年1月至2019年3月在MariMed Inc.担任高级副总裁，该公司在美国和国际上从事药用和娱乐大麻的种植、生产和分配（OTC：MRMD），并于2019年4月至2020年2月担任Halo Collective Inc.的首席战略官，并于2020年2月至2022年7月担任其总裁。Field女士于2005年获得斯坦福大学公共政策学士学位，并于2011年获得哥伦比亚大学工商管理硕士学位。
Katharyn Field has served as director and executive officer since June 2025 and served as independent director from October 2024 to June 2025. While serving Company, Ms. Field has also served as an independent director and audit committee member at Virpax Pharmaceuticals Inc., a specialty pharmaceutical company focused on pioneering advanced healthcare solutions with its flagship product leveraging proprietary liposomal encapsulation (Nasdaq: VRPX), since July 2024, has served as an independent director and audit committee member at iSpecimen Inc., a company that provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide (Nasdaq: ISPC), since September 2024, has served as the chief executive officer and the chairman of the board of directors at Halo Collective Inc., a company that engages in the cultivation, manufacture, transportation, and distribution of cannabis and cannabis extracts in Canada and the United States (OTC: HCANF), since July 2022, and has served as the interim chief executive officer and an executive director at Akanda Corporation, a company that engages in the cultivation, manufacture, and distribution of cannabis based products for medicinal use worldwide (Nasdaq: AKAN), since June 2022. Prior to joining Company, Ms. Field worked as a director at Costa Farms, a U.S. horticultural grower, from January 2013 to January 2017, worked as a consultant from January 2017 to January 2018, served as a senior vice president at MariMed Inc., a company that engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally (OTC: MRMD), from January 2018 to March 2019, and served as the chief strategy officer at Halo Collective Inc. from April 2019 to February 2020 and its president from February 2020 to July 2022. Ms. Field received her bachelor's degree in public policy from Stanford University in 2005 and her master of business administration degree from Columbia University in 2011. - Katharyn Field自2025年6月起担任董事和执行官，并于2024年10月至2025年6月担任独立董事。在为公司服务期间，Field女士还在Virpax Pharmaceuticals Inc.担任独立董事和审计委员会成员，该公司是一家专业制药公司，专注于凭借其旗舰产品利用专有脂质体封装（纳斯达克：VRPX）开创先进的医疗保健解决方案，自2024年7月起，在iSpecimen Inc.担任独立董事和审计委员会成员，该公司提供技术，将需要人类生物流体、组织和活细胞进行研究的生命科学研究人员与全球医疗保健提供者组织（纳斯达克：ISPC）中可用的生物样本连接起来，自2024年9月起，自2022年7月起担任Halo Collective Inc.的首席执行官和董事会主席，该公司是一家在加拿大和美国从事大麻和大麻提取物的种植、制造、运输和分销的公司（OTC：HCANF），自2022年6月起担任Akanda Corporation的临时首席执行官和执行董事，Akanda Corporation是一家在全球范围内从事基于大麻的药用产品的种植、制造和分销的公司（纳斯达克：AKAN）。在加入公司之前，Field女士曾于2013年1月至2017年1月在美国园艺种植商Costa Farms担任董事，于2017年1月至2018年1月担任顾问，于2018年1月至2019年3月在MariMed Inc.担任高级副总裁，该公司在美国和国际上从事药用和娱乐大麻的种植、生产和分配（OTC：MRMD），并于2019年4月至2020年2月担任Halo Collective Inc.的首席战略官，并于2020年2月至2022年7月担任其总裁。Field女士于2005年获得斯坦福大学公共政策学士学位，并于2011年获得哥伦比亚大学工商管理硕士学位。
- Katharyn Field has served as director and executive officer since June 2025 and served as independent director from October 2024 to June 2025. While serving Company, Ms. Field has also served as an independent director and audit committee member at Virpax Pharmaceuticals Inc., a specialty pharmaceutical company focused on pioneering advanced healthcare solutions with its flagship product leveraging proprietary liposomal encapsulation (Nasdaq: VRPX), since July 2024, has served as an independent director and audit committee member at iSpecimen Inc., a company that provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide (Nasdaq: ISPC), since September 2024, has served as the chief executive officer and the chairman of the board of directors at Halo Collective Inc., a company that engages in the cultivation, manufacture, transportation, and distribution of cannabis and cannabis extracts in Canada and the United States (OTC: HCANF), since July 2022, and has served as the interim chief executive officer and an executive director at Akanda Corporation, a company that engages in the cultivation, manufacture, and distribution of cannabis based products for medicinal use worldwide (Nasdaq: AKAN), since June 2022. Prior to joining Company, Ms. Field worked as a director at Costa Farms, a U.S. horticultural grower, from January 2013 to January 2017, worked as a consultant from January 2017 to January 2018, served as a senior vice president at MariMed Inc., a company that engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally (OTC: MRMD), from January 2018 to March 2019, and served as the chief strategy officer at Halo Collective Inc. from April 2019 to February 2020 and its president from February 2020 to July 2022. Ms. Field received her bachelor's degree in public policy from Stanford University in 2005 and her master of business administration degree from Columbia University in 2011.
- Archelle Georgiou
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Mika Grasso
-
米卡·格拉索是一家私人家族办公室的投资经理，负责评估公共和私人市场的投资机会。在担任投资经理之前，他曾于2023年11月至2025年3月期间担任Zions Capital Markets的财务助理，于2022年2月至2023年11月期间担任Paulson Investment Company的投资银行助理，于2021年8月至2022年2月期间担任高盛 Sachs的分析师，并于2020年5月至2021年8月期间担任Power Systems Management的Real Assets Team的分析师。Grasso先生在科罗拉多大学博尔德分校利兹商学院获得了金融硕士学位，主修投资管理和工商管理学士学位。
Mika Grasso,is an Investment Manager at a private family office, where he is responsible for evaluating investment opportunities across public and private markets. Prior to serving as an Investment Manager, he served as a Finance Associate for Zions Capital Markets from November 2023 until March 2025, Investment Banking Associate at Paulson Investment Company from February 2022 until November 2023, Analyst at Goldman Sachs from August 2021 to February 2022, and as an Analyst on the Real Assets Team at Power Systems Management from May 2020 to August 2021. Mr. Grasso received his MS in Finance with a concentration in Investment Management and BS in Business Administration from the University of Colorado Boulder, Leeds School of Business. - 米卡·格拉索是一家私人家族办公室的投资经理，负责评估公共和私人市场的投资机会。在担任投资经理之前，他曾于2023年11月至2025年3月期间担任Zions Capital Markets的财务助理，于2022年2月至2023年11月期间担任Paulson Investment Company的投资银行助理，于2021年8月至2022年2月期间担任高盛 Sachs的分析师，并于2020年5月至2021年8月期间担任Power Systems Management的Real Assets Team的分析师。Grasso先生在科罗拉多大学博尔德分校利兹商学院获得了金融硕士学位，主修投资管理和工商管理学士学位。
- Mika Grasso,is an Investment Manager at a private family office, where he is responsible for evaluating investment opportunities across public and private markets. Prior to serving as an Investment Manager, he served as a Finance Associate for Zions Capital Markets from November 2023 until March 2025, Investment Banking Associate at Paulson Investment Company from February 2022 until November 2023, Analyst at Goldman Sachs from August 2021 to February 2022, and as an Analyst on the Real Assets Team at Power Systems Management from May 2020 to August 2021. Mr. Grasso received his MS in Finance with a concentration in Investment Management and BS in Business Administration from the University of Colorado Boulder, Leeds School of Business.
- Gregory D. Waller
-
Gregory D. Waller ，他是Sunshine Heart公司的董事（2011年8月以来）。他也任职Endologix Corporation（上市公司）的董事会，目前担任审计委员会主席和提名和治理委员会成员，也是Ulthera公司（一个私营公司，销售超声波设备，用于非侵入性眉部）的首席财务官。从2006年3月到2011年4月，他曾担任Universal Building Products公司（混凝土施工配件制造商）的首席财务官。他曾担任Sybron Dental Specialties公司（牙科产品消费品的制造商和销售商）的财务副总裁、首席财务官和财务主管（从1993年8月到2005年5月退休）。他也曾担任Kerr公司、Ormco Corporation、Metrex公司的副总裁兼财务主管。他于1980年12月加入Ormco Corporation，担任副总裁、总会计师。他也曾担任Kerr European公司的运营副总裁（从1989年7月到1993年8月）。他持有加州州立大学富勒顿分校（California State University, Fullerton）的工商管理硕士学位（会计）。他也曾任职几家私人公司的董事，涉及Alsius Corporation一个上市公司，担任审计委员会主席和薪酬委员会的成员（从2007年6月到2009年9月被Zoll Medical Corporation收购）、 Biolase Technology公司（一家上市公司，担任审计委员会的主席）（从2009年10月到2010年8月）、 Cardiogenesis Corporation（公开交易的公司，公开交易的公司）、（从2007年4月到2011年5月被Cryolife公司收购）、Clarient公司（上市公司，于2010年12月被General Electric Company收购，担任审计委员会主席、薪酬和公司治理委员会的成员）（从2006年12月到2010年12月），SenoRx公司（一个于2010年7月被C.R.Bard公司收购的上市公司，担任审计委员会主席）（从2006年5月到2010年7月）。
Gregory D. Waller has served as a director of the Company since June 2017. He has also served as a board member of Nuwellis, Inc. since August 2011, a publicly traded company. From October 2011 to October 2015, Mr. Waller was Chief Financial Officer of Ulthera Corporation, a privately held company providing ultrasound technology for aesthetic and medical applications, which was sold to Merz North America in July 2014. From March 2006 until April 2011, Mr. Waller was Chief Financial Officer of Universal Building Products, a manufacturer of concrete construction accessories. Mr. Waller served as Vice President Finance, Chief Financial Officer and Treasurer of Sybron Dental Specialties, Inc., a manufacturer and marketer of consumable dental products, from August 1993 until his retirement in May 2005 and was formerly the Vice President and Treasurer of Kerr, Ormco Corporation, and Metrex. Mr. Waller's prior board experience includes service as a director for the following publicly traded companies: Endologix Corporation, from November 2003 to October 2020; Cardiogenesis Corporation, from April 2007 until its acquisition by Cryolife in 2011; Clarient, Inc., from December 2006 until its acquisition by General Electric Company in December 2010; Biolase Technology, Inc., from October 2009 to August 2010; SenoRx, Inc., from May 2006 until its acquisition by C.R. Bard, Inc. in July 2010; and Alsius Corporation, from June 2007 until its acquisition by Zoll Medical Corporation in September 2009. Mr. Waller has a Master of Business Administration with a concentration in accounting from California State University, Fullerton. - Gregory D. Waller ，他是Sunshine Heart公司的董事（2011年8月以来）。他也任职Endologix Corporation（上市公司）的董事会，目前担任审计委员会主席和提名和治理委员会成员，也是Ulthera公司（一个私营公司，销售超声波设备，用于非侵入性眉部）的首席财务官。从2006年3月到2011年4月，他曾担任Universal Building Products公司（混凝土施工配件制造商）的首席财务官。他曾担任Sybron Dental Specialties公司（牙科产品消费品的制造商和销售商）的财务副总裁、首席财务官和财务主管（从1993年8月到2005年5月退休）。他也曾担任Kerr公司、Ormco Corporation、Metrex公司的副总裁兼财务主管。他于1980年12月加入Ormco Corporation，担任副总裁、总会计师。他也曾担任Kerr European公司的运营副总裁（从1989年7月到1993年8月）。他持有加州州立大学富勒顿分校（California State University, Fullerton）的工商管理硕士学位（会计）。他也曾任职几家私人公司的董事，涉及Alsius Corporation一个上市公司，担任审计委员会主席和薪酬委员会的成员（从2007年6月到2009年9月被Zoll Medical Corporation收购）、 Biolase Technology公司（一家上市公司，担任审计委员会的主席）（从2009年10月到2010年8月）、 Cardiogenesis Corporation（公开交易的公司，公开交易的公司）、（从2007年4月到2011年5月被Cryolife公司收购）、Clarient公司（上市公司，于2010年12月被General Electric Company收购，担任审计委员会主席、薪酬和公司治理委员会的成员）（从2006年12月到2010年12月），SenoRx公司（一个于2010年7月被C.R.Bard公司收购的上市公司，担任审计委员会主席）（从2006年5月到2010年7月）。
- Gregory D. Waller has served as a director of the Company since June 2017. He has also served as a board member of Nuwellis, Inc. since August 2011, a publicly traded company. From October 2011 to October 2015, Mr. Waller was Chief Financial Officer of Ulthera Corporation, a privately held company providing ultrasound technology for aesthetic and medical applications, which was sold to Merz North America in July 2014. From March 2006 until April 2011, Mr. Waller was Chief Financial Officer of Universal Building Products, a manufacturer of concrete construction accessories. Mr. Waller served as Vice President Finance, Chief Financial Officer and Treasurer of Sybron Dental Specialties, Inc., a manufacturer and marketer of consumable dental products, from August 1993 until his retirement in May 2005 and was formerly the Vice President and Treasurer of Kerr, Ormco Corporation, and Metrex. Mr. Waller's prior board experience includes service as a director for the following publicly traded companies: Endologix Corporation, from November 2003 to October 2020; Cardiogenesis Corporation, from April 2007 until its acquisition by Cryolife in 2011; Clarient, Inc., from December 2006 until its acquisition by General Electric Company in December 2010; Biolase Technology, Inc., from October 2009 to August 2010; SenoRx, Inc., from May 2006 until its acquisition by C.R. Bard, Inc. in July 2010; and Alsius Corporation, from June 2007 until its acquisition by Zoll Medical Corporation in September 2009. Mr. Waller has a Master of Business Administration with a concentration in accounting from California State University, Fullerton.
- John L. Erb
-
John L. Erb ，他一直担任Sunshine Heart公司的董事（2012年9月以来），以及董事会主席（2012年10月以来）。他目前担任 Cardia Access公司（医疗设备公司，参与开发新设备用于治疗心脏病）的首席执行官（2007年2月以来）。他于2007年担任CHF Solutions公司（一个医疗设备公司，参与开发、生产和销售治疗充血性心力衰竭的设备）的执行董事会主席。从2001年到2006年，他是CHF Solutions公司的首席执行官。此前，他曾担任IntraTherapeutics公司（医疗设备公司，参与开发、制造和分销外围血管支架）的总裁兼首席执行官（从1997年到2001年）。此前，他曾担任Schneider Worldwide公司（Pfizer公司的一个部门）的全球运营副总裁。他曾担任SenoRx公司（上市公司）的董事（从2001年12月到2010年7月），也曾担任CryoCath Technologies公司（加拿大上市公司）的董事（从2000年10月到2008年12月）。他目前担任Cardia Access公司、Osprey Medical公司（澳大利亚证券交易所上市）、 Vascular Solutions公司（纳斯达克上市公司，他曾任职董事会）的董事（2002年以来）。他持有加州州立大学富勒尔顿分校（California State University, Fullerton）的工商管理学士学位（财务）。他曾担任VivoMetrics公司（私营公司）的董事。VivoMetrics公司于2010年4月根据美国破产法第11章提交了一份请愿书，并于2012年10月摆脱破产。除了前面的句子中描述和下面的披露，在过去十年没有其他事件发生，要求按照S-K规则401f项目披露。
John L. Erb has served as chief executive officer and president of CHF Solutions, Inc. Nasdaq: CHFS since 2015 and as a member of its board of directors and chairman since 2012. He has also served as chief executive officer and chairman of NeuroMedic, Inc., a private company he co-founded, since 2014. Previously, Mr. Erb served as chief executive officer, from 2007 to 2018 of NuAx, Inc. (formerly Cardia Access, Inc.), a private medical device company involved in developing new devices for the treatment of heart disease. Mr. Erb's prior board experience includes service as a director of SenoRx, Inc., then a Nasdaq-listed company, from 2001 until its acquisition in 2010; and as chairman of the board of Vascular Solutions, Inc., then a Nasdaq-listed company, until its acquisition in 2017. Mr. Erb currently serves as chairman of the board of Osprey Medical, Inc. (ASX:OSP) and as a director of MiroMatrix, a private biotechnology company, since 2017. Mr. Erb has a Bachelor of Arts, Business Administration, concentration in finance from California State University. - John L. Erb ，他一直担任Sunshine Heart公司的董事（2012年9月以来），以及董事会主席（2012年10月以来）。他目前担任 Cardia Access公司（医疗设备公司，参与开发新设备用于治疗心脏病）的首席执行官（2007年2月以来）。他于2007年担任CHF Solutions公司（一个医疗设备公司，参与开发、生产和销售治疗充血性心力衰竭的设备）的执行董事会主席。从2001年到2006年，他是CHF Solutions公司的首席执行官。此前，他曾担任IntraTherapeutics公司（医疗设备公司，参与开发、制造和分销外围血管支架）的总裁兼首席执行官（从1997年到2001年）。此前，他曾担任Schneider Worldwide公司（Pfizer公司的一个部门）的全球运营副总裁。他曾担任SenoRx公司（上市公司）的董事（从2001年12月到2010年7月），也曾担任CryoCath Technologies公司（加拿大上市公司）的董事（从2000年10月到2008年12月）。他目前担任Cardia Access公司、Osprey Medical公司（澳大利亚证券交易所上市）、 Vascular Solutions公司（纳斯达克上市公司，他曾任职董事会）的董事（2002年以来）。他持有加州州立大学富勒尔顿分校（California State University, Fullerton）的工商管理学士学位（财务）。他曾担任VivoMetrics公司（私营公司）的董事。VivoMetrics公司于2010年4月根据美国破产法第11章提交了一份请愿书，并于2012年10月摆脱破产。除了前面的句子中描述和下面的披露，在过去十年没有其他事件发生，要求按照S-K规则401f项目披露。
- John L. Erb has served as chief executive officer and president of CHF Solutions, Inc. Nasdaq: CHFS since 2015 and as a member of its board of directors and chairman since 2012. He has also served as chief executive officer and chairman of NeuroMedic, Inc., a private company he co-founded, since 2014. Previously, Mr. Erb served as chief executive officer, from 2007 to 2018 of NuAx, Inc. (formerly Cardia Access, Inc.), a private medical device company involved in developing new devices for the treatment of heart disease. Mr. Erb's prior board experience includes service as a director of SenoRx, Inc., then a Nasdaq-listed company, from 2001 until its acquisition in 2010; and as chairman of the board of Vascular Solutions, Inc., then a Nasdaq-listed company, until its acquisition in 2017. Mr. Erb currently serves as chairman of the board of Osprey Medical, Inc. (ASX:OSP) and as a director of MiroMatrix, a private biotechnology company, since 2017. Mr. Erb has a Bachelor of Arts, Business Administration, concentration in finance from California State University.
高管简历
中英对照 | 中文 | 英文- Neil P. Ayotte, Esq
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Carisa Schultz
Carisa Schultz，最近于2024年4月至2025年11月担任NeueHealth（前身为Bright Health Group）的财务副总裁，该公司是一家在纽约证券交易所上市的医疗保健公司，负责领导所有企业财务、财务和企业发展活动。在担任该职务之前，她曾于2022年4月至2024年4月担任企业财务副总裁，并于2020年9月至2022年4月担任财务总监。她曾于2019年10月至2020年7月担任Starkey Hearing Technologies的高级商业智能分析师，领导支持美国零售销售组织的所有商业智能活动，2015年2月至2019年9月担任Highline Labs的分析总监和临时财务总监，领导分析和收入周期管理团队，并于2012年7月至2015年2月担任Wavelength Group的首席财务顾问和总裁，该咨询公司为多个行业的客户提供战略FP & A和销售运营专业知识。在她职业生涯的早期，她曾在Big 4 Public Accounting工作，之后在波士顿科学从事公司财务工作，在创立Wavelength Group之前，她还在泰尔茂心血管系统公司晋升为财务经理。Schultz女士在明尼苏达大学Curtis L. Carlson管理学院获得商业理学学士学位和会计学学位。
Carisa Schultz,most recently served as Vice President, Finance for NeueHealth (formerly Bright Health Group), a health care company that was publicly traded on NYSE, from April 2024 to November 2025, where she led all enterprise finance, treasury and corporate development activities. Prior to that role, she served as Associate Vice President, Enterprise Finance from April 2022 to April 2024, and as Director, Finance from September 2020 to April 2022. She previously served as Senior Business Intelligence Analyst for Starkey Hearing Technologies from October 2019 until July 2020, where she led all Business Intelligence activities supporting the US Retail Sales organization, as Director of Analytics and Interim Controller at Highline Labs from February 2015 until September 2019, where she led the Analytics and Revenue Cycle Management team, and as Lead Financial Consultant and President at The Wavelength Group, a consulting firm providing strategic FP&A and sales operations expertise to clients across multiple industries from July 2012 to February 2015. Earlier in her career, she worked in Big 4 public accounting before moving into corporate finance at Boston Scientific and also advanced to Finance Manager at Cardiovascular Systems Inc. before founding The Wavelength Group. Ms. Schultz received her Bachelor of Science of Business, Accounting degree from the University of Minnesota, Curtis L. Carlson School of Management.- Carisa Schultz，最近于2024年4月至2025年11月担任NeueHealth（前身为Bright Health Group）的财务副总裁，该公司是一家在纽约证券交易所上市的医疗保健公司，负责领导所有企业财务、财务和企业发展活动。在担任该职务之前，她曾于2022年4月至2024年4月担任企业财务副总裁，并于2020年9月至2022年4月担任财务总监。她曾于2019年10月至2020年7月担任Starkey Hearing Technologies的高级商业智能分析师，领导支持美国零售销售组织的所有商业智能活动，2015年2月至2019年9月担任Highline Labs的分析总监和临时财务总监，领导分析和收入周期管理团队，并于2012年7月至2015年2月担任Wavelength Group的首席财务顾问和总裁，该咨询公司为多个行业的客户提供战略FP & A和销售运营专业知识。在她职业生涯的早期，她曾在Big 4 Public Accounting工作，之后在波士顿科学从事公司财务工作，在创立Wavelength Group之前，她还在泰尔茂心血管系统公司晋升为财务经理。Schultz女士在明尼苏达大学Curtis L. Carlson管理学院获得商业理学学士学位和会计学学位。
- Carisa Schultz,most recently served as Vice President, Finance for NeueHealth (formerly Bright Health Group), a health care company that was publicly traded on NYSE, from April 2024 to November 2025, where she led all enterprise finance, treasury and corporate development activities. Prior to that role, she served as Associate Vice President, Enterprise Finance from April 2022 to April 2024, and as Director, Finance from September 2020 to April 2022. She previously served as Senior Business Intelligence Analyst for Starkey Hearing Technologies from October 2019 until July 2020, where she led all Business Intelligence activities supporting the US Retail Sales organization, as Director of Analytics and Interim Controller at Highline Labs from February 2015 until September 2019, where she led the Analytics and Revenue Cycle Management team, and as Lead Financial Consultant and President at The Wavelength Group, a consulting firm providing strategic FP&A and sales operations expertise to clients across multiple industries from July 2012 to February 2015. Earlier in her career, she worked in Big 4 public accounting before moving into corporate finance at Boston Scientific and also advanced to Finance Manager at Cardiovascular Systems Inc. before founding The Wavelength Group. Ms. Schultz received her Bachelor of Science of Business, Accounting degree from the University of Minnesota, Curtis L. Carlson School of Management.
- John L. Erb
John L. Erb ，他一直担任Sunshine Heart公司的董事（2012年9月以来），以及董事会主席（2012年10月以来）。他目前担任 Cardia Access公司（医疗设备公司，参与开发新设备用于治疗心脏病）的首席执行官（2007年2月以来）。他于2007年担任CHF Solutions公司（一个医疗设备公司，参与开发、生产和销售治疗充血性心力衰竭的设备）的执行董事会主席。从2001年到2006年，他是CHF Solutions公司的首席执行官。此前，他曾担任IntraTherapeutics公司（医疗设备公司，参与开发、制造和分销外围血管支架）的总裁兼首席执行官（从1997年到2001年）。此前，他曾担任Schneider Worldwide公司（Pfizer公司的一个部门）的全球运营副总裁。他曾担任SenoRx公司（上市公司）的董事（从2001年12月到2010年7月），也曾担任CryoCath Technologies公司（加拿大上市公司）的董事（从2000年10月到2008年12月）。他目前担任Cardia Access公司、Osprey Medical公司（澳大利亚证券交易所上市）、 Vascular Solutions公司（纳斯达克上市公司，他曾任职董事会）的董事（2002年以来）。他持有加州州立大学富勒尔顿分校（California State University, Fullerton）的工商管理学士学位（财务）。他曾担任VivoMetrics公司（私营公司）的董事。VivoMetrics公司于2010年4月根据美国破产法第11章提交了一份请愿书，并于2012年10月摆脱破产。除了前面的句子中描述和下面的披露，在过去十年没有其他事件发生，要求按照S-K规则401f项目披露。
John L. Erb has served as chief executive officer and president of CHF Solutions, Inc. Nasdaq: CHFS since 2015 and as a member of its board of directors and chairman since 2012. He has also served as chief executive officer and chairman of NeuroMedic, Inc., a private company he co-founded, since 2014. Previously, Mr. Erb served as chief executive officer, from 2007 to 2018 of NuAx, Inc. (formerly Cardia Access, Inc.), a private medical device company involved in developing new devices for the treatment of heart disease. Mr. Erb's prior board experience includes service as a director of SenoRx, Inc., then a Nasdaq-listed company, from 2001 until its acquisition in 2010; and as chairman of the board of Vascular Solutions, Inc., then a Nasdaq-listed company, until its acquisition in 2017. Mr. Erb currently serves as chairman of the board of Osprey Medical, Inc. (ASX:OSP) and as a director of MiroMatrix, a private biotechnology company, since 2017. Mr. Erb has a Bachelor of Arts, Business Administration, concentration in finance from California State University.- John L. Erb ，他一直担任Sunshine Heart公司的董事（2012年9月以来），以及董事会主席（2012年10月以来）。他目前担任 Cardia Access公司（医疗设备公司，参与开发新设备用于治疗心脏病）的首席执行官（2007年2月以来）。他于2007年担任CHF Solutions公司（一个医疗设备公司，参与开发、生产和销售治疗充血性心力衰竭的设备）的执行董事会主席。从2001年到2006年，他是CHF Solutions公司的首席执行官。此前，他曾担任IntraTherapeutics公司（医疗设备公司，参与开发、制造和分销外围血管支架）的总裁兼首席执行官（从1997年到2001年）。此前，他曾担任Schneider Worldwide公司（Pfizer公司的一个部门）的全球运营副总裁。他曾担任SenoRx公司（上市公司）的董事（从2001年12月到2010年7月），也曾担任CryoCath Technologies公司（加拿大上市公司）的董事（从2000年10月到2008年12月）。他目前担任Cardia Access公司、Osprey Medical公司（澳大利亚证券交易所上市）、 Vascular Solutions公司（纳斯达克上市公司，他曾任职董事会）的董事（2002年以来）。他持有加州州立大学富勒尔顿分校（California State University, Fullerton）的工商管理学士学位（财务）。他曾担任VivoMetrics公司（私营公司）的董事。VivoMetrics公司于2010年4月根据美国破产法第11章提交了一份请愿书，并于2012年10月摆脱破产。除了前面的句子中描述和下面的披露，在过去十年没有其他事件发生，要求按照S-K规则401f项目披露。
- John L. Erb has served as chief executive officer and president of CHF Solutions, Inc. Nasdaq: CHFS since 2015 and as a member of its board of directors and chairman since 2012. He has also served as chief executive officer and chairman of NeuroMedic, Inc., a private company he co-founded, since 2014. Previously, Mr. Erb served as chief executive officer, from 2007 to 2018 of NuAx, Inc. (formerly Cardia Access, Inc.), a private medical device company involved in developing new devices for the treatment of heart disease. Mr. Erb's prior board experience includes service as a director of SenoRx, Inc., then a Nasdaq-listed company, from 2001 until its acquisition in 2010; and as chairman of the board of Vascular Solutions, Inc., then a Nasdaq-listed company, until its acquisition in 2017. Mr. Erb currently serves as chairman of the board of Osprey Medical, Inc. (ASX:OSP) and as a director of MiroMatrix, a private biotechnology company, since 2017. Mr. Erb has a Bachelor of Arts, Business Administration, concentration in finance from California State University.